Injection of anti-IgE antibodies will suppress IgE and allergic symptoms

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 54, Issue 2, 1999, Pages 103-110

  Patalano, F ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CGP 51901; CHIMERIC ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; UNCLASSIFIED DRUG;

ALLERGY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; ATOPY; B LYMPHOCYTE ACTIVATION; HUMAN; IMMUNOREGULATION; IMMUNOTHERAPY; MEDIATOR RELEASE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ASTHMA; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; RHINITIS, ALLERGIC, SEASONAL;

EID: 0033040922     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. 1. Noelle RJ, McCann J, Marshall L, Bartlett WC. Cognate interactions between helper T cells and B cells, III. Contact-dependent, lymphokine-independent induction of B cell cycle entry by activated helper T cells. J Immunol 1989;143:1807-1814.
2. 2. Vercelli D, Geha R. Regulation of IgE synthesis in humans. J Clin Immunol 1989;9:75-83.
3. 3. Vitetta ES, Fernandez-Botran R, Myers CD, Sanders VM. Cellular interactions in the immune response. Adv Immunol 1989;45:1-105.
4. 4. Bradding P, Roberts J, Britten K, et al. IL-4, -5, -6 and TNFα in normal and asthmatic airways: evidence of the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994;10:471-480.
5. 5. Okayama Y, Petit-Frere C, Kassel O, et al. IgE-dependent expression of mRNA for IL-4 and IL-5 in human lung mast cells. J Immunol 1995;155:1796-1808.
6. εR1) mediates IgE-dependent allergen presentation. J Immunol 1995;154:6285-6290.
7. εR1 expression on monocytes from non-atopic donors. Clin Exp Allergy 1996;26:630-641.
8. 8. Pirron U, Schlunk T, Prinz J, Rieber E. IgE dependent antigen focusing by human B lymphocytes is mediated by the low affinity receptor for IgE. Eur J Immunol 1990;20:1547-1551.
9. 9. Coyle A, Wagner K, Bertrand C, Tsuyuki S, Bews J, Heusser C. Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody. J Exp Med 1996;183:1303-1310.
10. 10. Brusselle G, Kips J, Tavernier J, et al. Attenuation of allergic airway inflammation in IL-4 deficient mice. Clin Exp Allergy 1994;24:73-80.
11. 11. Heusser C, Jardieu P. Therapeutic potential of anti-IgE antibodies. Curr Opin Immunol 1998;9:805-814.
12. 12. Jardieu P. Anti-IgE therapy. Curr Opin Immunol 1995;7:779-782.
13. 13. Shimoda K, van Deuren J, Sangster MY, et al. Lack of IL-4 induced Th2 responses and IgE class switching in mice with disrupted Stat6 gene. Nature 1996;380:630-633.
14. 14. Paul WE. Interleukin 4: signalling mechanisms and control of T cell differentiation. Ciba Found Symp 1997;204:208-216.
15. 15. Flores-Romo L, Shields J, Hubert Y, et al. Inhibition of an in vivo antigen-specific IgE response by antibodies to CD23. Science 1993;261:1036-1041.
16. 16. Peat JK, Toelle BG, Dermand J, van den Berg R, Britton WJ, Woolcock AJ. Serum IgE levels, atopy and asthma in young adults: results from a longitudinal cohort study. Allergy 1996;51:804-810.
17. 17. Khazaeli MB, Saleh MN, Wheeler RH, et al. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response. J Natl Cancer Inst 1988;80:937-947.
18. 18. Jaffers GJ, Fuller TC, Cosimi AB, Russel PS, Winn HJ, Colvin RB. Monoclonal antibody therapy: anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression. Transplantation 1986;41:572-578.
19. 19. Shawler DL, Bartholomew RM, Smith LM, Dillman RO. Human immune response to multiple injection of murine monoclonal IgG. J Immunol 1985;135:1530-1535.
20. 20. Sears HF, Herlyn D, Steplewski Z, Koprowski H. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Response Mod 1984;3:138-150.
21. 21. Miller RA, Oseroff AR, Stratte PT, Levy R. Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 1983;62:988-995.
22. 22. Kolbinger F, Saldanha J, Hardman N, Mendig MM. Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies. Protein Eng 1993;6:971-980.
23. 23. Presta L, Lahr S, Shields R, et al. Humanization of an antibody directed against Immunoglobulin E. J Immunol 1993;151:2623-2632.
24. 24. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A 1984;81:6851-6855.
25. 25. Reichmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988;332:323-327.
26. 26. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in human antibody with those from a mouse. Nature 1986;321:522-525.
27. 27. Amit AG, Mariuzza RA, Phillips SEV, Poljak RJ. Three-dimensional structure of an antigen-antibody complex at 2.8 Å resolution. Science 1986;233:747-753.
28. 28. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185 HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992;89:4285-4289.
29. 29. Corne J, Djukanovic R, Thomas L, et al. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: Efficacy, safety and pharmacokinetics. J Clin Invest 1997;99:879-887.
30. 30. Togias A, Corren J, Shapiro G, et al. Anti-IgE treatment reduces skin test (ST) reactivity. J Allergy Clin Immunol 1998;101(1 pt 2):s171 [Abstract 706].
31. 31. Racine-Poon A, Botta L, Chang TW, et al. Efficacy, pharmacodynamics and pharmacokinetics of CGP 51901, an antiimmunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis. Clin Pharmacol Ther 1997;62:675-690.
32. 32. Casale TB, Bernstein IL, Busse WW, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997;100:110-121.
33. 33. Cockcroft DW, Murdock KY. Comparative effects of inhaled salbutamol, sodium cromoglycate and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and bronchial responsiveness to histamine. J Allergy Clin Immunol 1987;79:734-740.
34. 2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. Am J Respir Crit Care Med 1995;152:1485-1489.
35. 35. Boulet L-P, Chapman KR, Coté J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997;155:1835-1840.
36. 2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. Am J Respir Crit Care Med 1995;152:1485-1489.
37. 37. Fahy JV, Flemming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early-and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1828-1834.
38. 38. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin test reactivity to allergens. N Engl J Med 1989;320:271-277.
39. 39. Sears MR, Burrows B, Flannery EM, Herbison GB, Hewitt CJ, Holdaway MD. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991;325:1067-1071.
40. 40. Sunyer J, Munoz A the Spanish Group of the European Asthma Study. Concentration of methacholine for bronchial responsiveness according to symptoms, smoking and immunoglobulin E in a population based study in Spain. Am J Respir Crit Care Med 1996;153:1273-1279.
41. 41. Pollart S, Chapman M, Fiocco G, Rose G, Platts-Mills A. Epidemiology of acute asthma: IgE antibodies to common inhalant allergens as a risk factor for emergency room visits. J Allergy Clin Immunol 1989;83:875-882.
42. 42. Fick RB, Simon SJ, Su JQ, Zeiger R, and the E25 Study Group. Anti-IgE (rhumAb) treatment of the symptoms of moderate to severe allergic asthma. Ann Asthma Allergy Immunol 1998;80:80 [Abstract 8].
43. 43. Metzger WJ, Fick RB, and the E25 Asthma Study Group. Corticosteroid (CS) withdrawal in a study of recombinant humanized monoclonal antibody to IgE (RhumAb E25). J Allergy Clin Immunol 1998;101(1 pt 2):s231 [Abstract 960].